Claims for Patent: 10,407,673

Summary for Patent: 10,407,673

Title:	Methods for glycoprotein remodeling using endoglycosidase mutants
Abstract:	A mutant of EndoS2 includes one or more mutations in the sequence of a wild-type EndoS2 (SEQ ID NO:1), wherein the one or more mutations are in a peptide region located within residues 133-143, residues 177-182, residues 184-189, residues 221-231, and/or residues 227-237, wherein the mutant of EndoS2 has a low hydrolyzing activity and a high tranglycosylation activity, as compared to those of the wild-type EndoS2. A method for preparing an engineered glycoprotein using the mutant of EndoS2 includes coupling an activated oligosaccharide to a glycoprotein acceptor. The activated oligosaccharide is a glycan oxazoline.
Inventor(s):	Lin; Nan-Horng (Vernon Hills, IL), Huang; Lin-Ya (New Taipei, TW), Shivatare; Sachin S (Taipei, TW), Chen; Li-Tzu (Taipei, TW), Wong; Chi-Huey (Taipei, TW), Wu; Chung-Yi (New Taipei, TW), Cheng; Ting (Keelung, TW)
Assignee:	CHO Pharma Inc. (Taipei, TW) Academia Sinica (Taipei, TW)
Application Number:	16/011,622
Patent Claims:	1. A method for preparing an engineered glycoprotein using a mutant endoglycosidase S2 (EndoS2), comprising coupling an activated oligosaccharide to a glycoprotein acceptor, wherein the mutant EndoS2 comprises one or more mutations in the sequence of a wild-type EndoS2 as set forth in SEQ ID NO:1, wherein the one or more mutations are in a peptide region located within residues 133-143, residues 177-178 residue 182, residues 187-189, residues 221-231, and residues 232-237, wherein the mutant of EndoS2 has a hydrolyzing activity lower than that of the wild-type EndoS2 and has a tranglycosylation activity higher than that of the wild-type EndoS2, and wherein the mutation at residue 182 is D I82Q. 2. The method according to claim 1, wherein the one or more mutations are at residues T138, D226, T227, and/or T228. 3. The method according to claim 1, wherein the one or more mutations are selected from the group consisting of T138D, T138E, T138F, T138H, T138K, T138L, T138M, T138N, T138Q, T138R, T138V, T138W, D226Q, T227Q, and T228Q. 4. The method according to claim 1, wherein the mutant comprises the sequence of SEQ ID NO.6, SEQ ID NO.7, SEQ ID NO.8, SEQ ID NO.9, SEQ ID NO.10, SEQ ID NO.11, SEQ ID NO.12, SEQ ID NO.13, SEQ ID NO.14, SEQ ID NO.15, SEQ ID NO.16, SEQ ID NO.17, SEQ ID NO. 2, SEQ ID NO. 3, SEQ ID NO. 4, or SEQ ID NO. 5. 5. The method according to claim 1, wherein the activated oligosaccharide is a glycan oxazoline. 6. The method according to claim 5, wherein the glycan oxazoline comprises an N-glycan having the following formula: ##STR00006## wherein R.sup.1 is --H or N-acetyl glucosamine attached via a .beta.-1,4 linkage, and R.sup.2 and R.sup.3 are same or different and are independently selected from the group consisting of: mannosyl-(Man), di-mannosyl-(Man.sub.2), tri-mannosyl-(Man.sub.3), biantennary penta-mannosyl-(Man.sub.2-(Man.sub.2)Man), biantennary tetra-mannosyl-(Man.sub.2-(Man)Man), biantennary tri-mannosyl-(Man-(Man)Man), N-acetylglucosamine-mannosyl-(GlcNac-Man), galactose-N-acetylglucosamine-mannosyl-(Gal-GlcNAc-Man), N-acetylneuraminic acid-galactose-N-acetylglucosamine-mannosyl-(Nur5Ac-Gal-GlcNAc-Man), biantennary di-N-acetylglucosamine-mannosyl(GlcNAc).sub.2-Man), biantennary di-(galactose-N-acetylglucosamine)-mannosyl-((Gal-GlcNAc).sub.2-Man), biantennary di-(N-acetyl-neuraminic acid-galactose-N-acetylglucosamine)-mannosyl-((Neu5Ac-Gal-GlcNAc).sub.2-M- an), galactose-(fucosyl-N-acetylglucosamine)-mannosyl-(Gal-(Fuc-GlcNAc)-Ma- n), N-acetylneuraminic acid-galactose-(fucosyl-N-acetylglucosamine)-mannosyl-((Neu5Ac-Gal-(Fuc-G- lcNAc)-Man), fucosyl-galactose-N-acetylglucosamine-mannosyl-fucosyl-galactose-(fucosyl- -N-acetylglucosamine)-mannosyl-(Fuc-Gal-GlcNAc-Man), N-neuraminic acid-(fucose-galactose)-N-acetylglucosamine-mannosyl-(Nur5Ac-(Fuc-Gal)-Gl- cNAc-Man), fucose-galactose-(fucose-N-acetylglucosamine)-mannosyl-(Fuc-Gal- -(Fuc-GlcNAc)-Man), N-neuraminic acid-(fucose-galactose)-(fucose-N-acetylglucosamine)-mannosyl-(Neu5Ac-(Fu- c-Gal)-(Fuc-GlcNAc)-Man), (galactose-N-acetylglucosamine).sub.n-galactose-N-acetylglucosamine-manno- syl-(Gal-GlcNAc).sub.n-Gal-GlcNAc-Man), (galactose-N-acetylglucosamine).sub.n-galactose-(fucose-N-acetylglucosami- ne)-mannosyl-((Gal-GlcNAc).sub.n-Gal-(Fuc-GlcNAc)-Man), N-acetylneuraminic acid-(galactose-N-acetylglucosamine).sub.n-galactose-N-acetylglucosamine)- -mannosyl-(Neu5Ac-(Gal-GlcNAc).sub.n-Gal-GlcNAc-Man), and N-acetylneuraminic acid-(galactose-N-acetylglucosamine).sub.n-galactose-(fucose-N-acetylgluc- osamine)-mannosyl-(Neu5Ac-(Gal-GlcNAc).sub.n-Gal-(Fuc-GlcNAc)-Man), wherein n is an integer from 1 to 3. 7. The method according to claim 1, wherein the glycoprotein acceptor contains a GlcNAc monosaccharide. 8. The method according to claim 1, wherein the glycoprotein acceptor is a non-fucosylated GlcNAc-acceptor. 9. The method according to claim 1, wherein the glycoprotein acceptor is a glycopeptide, a glycoprotein, an antibody or a fragment thereof. 10. The method according to claim 1, wherein the glycoprotein acceptor is a core fucosylated or non-fucosylated GlcNAC-IgG acceptor or a fragment thereof. 11. The method according to claim 1, wherein the GlcNAC-IgG acceptor is derived from a monoclonal antibody selected from the group consisting of cetuximab, rituximab, muromonab-CD3, abciximab, daclizumab, basiliximab, palivizumab, infliximab, trastuzumab, gemtuzumab ozogamicin, alemtuzumab, ibritumomab tiuxetan, adalimumab, omalizumab, tositumomab, 1-131 tositumomab, efalizumab, bevacizumab, panitumumab, pertuzumab, natalizumab, etanercept, IGN101, volociximab, Anti-CD80 mAb, Anti-CD23 mAb, CAT-3888, CDP-791, eraptuzumab, MDX-010, MDX-060, MDX-070, matuzumab, CP-675,206, CAL, SGN-30, zanolimumab, adecatumumab, oregovomab, nimotuzumab, ABT-874, denosumab, AM 108, AMG 714, fontolizumab, daclizumab, golimumab, CNTO 1275, ocrelizumab, HuMax-CD20, belimumab, epratuzumab, MLN1202, visilizumab, tocilizumab, ocrerlizumab, certolizumab pegol, eculizumab, pexelizumab, abciximab, ranibizimumab. 12. A method for treating cancer, comprising administering to a subject in need thereof an effective amount of a glycoprotein prepared by the method of claim 1.

Details for Patent 10,407,673

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Janssen Biotech, Inc.	REOPRO	abciximab	Injection	103575	12/22/1994		2036-08-24
Genentech, Inc.	RITUXAN	rituximab	Injection	103705	11/26/1997		2036-08-24
Hoffmann-la Roche Inc.	ZENAPAX	daclizumab	Injection	103749	12/10/1997		2036-08-24
Novartis Pharmaceuticals Corporation	SIMULECT	basiliximab	For Injection	103764	05/12/1998		2036-08-24